Oncology

The Version 3.2025 update adds tislelizumab-based regimens as preferred first-line treatments and introduces new dosing schedules for PD-L1–positive esophageal squamous cell carcinoma.

Clinicians should not just focus on one single nucleotide polymorphism (SNP), but rather consider all SNPs because each factor causes unique adverse effects

Breast cancer treatment is highly individualized and based on the stage, hormone receptor status, HER2 expression, and patient-specific factors.

Continuing education supports pharmacy technician career advancement, retention, and skill development.

The meaningful results were reported in the DESTINY-Breast09 trial.

Delayed pegaspargase reduces hepatotoxicity without affecting outcomes.

Real-world data support momelotinib as an effective and well-tolerated treatment for myelofibrosis-related anemia.

The 2025 SPPCP Virtual Conference on Tuesday, May 20, 2025, will offer pharmacists and clinicians a full day of CE-accredited sessions on complex pain management, opioid use disorder, mentorship, and innovative approaches in palliative care, with opportunities for networking and professional development.

Sequencing of antibody-drug conjugates (ADCs) in HER2-mutated breast cancer is crucial for optimizing treatment outcomes.

Antibody-drug conjugates have revolutionized metastatic breast cancer treatment and classification.

Undetectable minimal residual disease rates improved with ongoing therapy.

The data showed improvements in overall response rates, progression-free survival, and duration of response.

Medically integrated pharmacies improve collaboration, patient care, communication, and therapy management.

A palliative care pharmacist highlights a spectrum of clinical opportunities for patients, caregivers, and clinicians when rounding at the bedside.

The high acceptance rates of these interventions demonstrate the key role in optimizing patient care that clinical oncology pharmacists with access to medical records play.

Current treatment strategies are aimed at reducing hematocrit and symptom burden through phlebotomy, aspirin, and cytoreductive agents, while emerging therapies offer promise for better disease control and quality of life.

Imlunestrant is an investigational, brain-penetrating, oral selective degrader of estrogen receptor.

There are no clearly defined, widely accepted clinical pharmacist metrics.

Scott A. Soefje, PharmD, MBA, BCOP, explained how the expanding use of the FDA’s 505(b)(2) drug approval pathway is creating operational and reimbursement challenges for oncology infusion centers.

Jessica Davis, PharmD, BCOP highlights the role of pharmacy technicians in ambulatory oncology clinic settings.

Patients with unresectable or metastatic hepatocellular carcinoma (HCC) receiving this regimen had favorable median overall survival (23.7 months) compared with standard of care (20.6 months).

In business, growth for the sake of growth mirrors the ideology of the cancer cell.

This approval marks bevacizumab-nwgd as the sixth reference product to bevacizumab (Avastin).

Metrics should empower pharmacists rather than burden them.

Lauren Dietz, PharmD, highlighted the role of oncology pharmacists in guiding prophylaxis decisions to optimize transplant outcomes.

Julia Ziegengeist, PharmD, BCOP offers insights for pharmacists navigating adjuvant and neoadjuvant treatment of breast cancer.

Christine Barrett, PharmD, BCOP, addressed advances in the treatment of stage III melanoma that provide the potential to improve long-term outcomes by enhancing immune response, tailoring surgical approaches, and refining patient selection strategies.

Mark Zangardi, PharmD, MS, BCOP, and Amber Cipriani, PharmD, BCOP, discuss the growing role of circulating tumor DNA (ctDNA) testing in oncology, highlighting its applications in early cancer detection, molecular residual disease assessment, and treatment monitoring.